Latest Asx News

XTC Lithium's latest quarterly report reveals significant gold and lithium anomalies from an extensive auger drilling program at its Southern Cross project, highlighting promising exploration potential.

Aspire Mining Limited has made significant strides in developing its Ovoot Coking Coal Project, progressing construction tenders and customer engagement despite a challenging coal market.

ReNu Energy reports progress on a management buyout proposal for its hydrogen subsidiary and completes sale of legacy geothermal assets, signaling a strategic pivot and ongoing capital challenges.

Kinetiko Energy reports mixed results from its five-well gas production test program, with the first well underperforming but the company maintaining optimism for the remaining wells and a strong financial footing.

Thunderbird Resources has significantly bolstered its portfolio with the acquisition of the Rockvale and Kookabookra antimony-gold projects in New South Wales, alongside promising uranium exploration results in Canada. These developments position the company for a dynamic 2025 exploration season.

HITIQ Limited’s largest shareholder, Harmil Angel Investments, is converting $1.6 million in convertible notes into shares, while the company revamps its advisory mandate to attract US investors.

Excite Technology Services has achieved positive EBITDA in December 2024, driven by strong revenue growth and record customer receipts, notably from its Digital Forensics division and the integration of CDFS.

Group 6 Metals Limited reveals a challenging quarter marked by safety incidents and production setbacks at its Dolphin Tungsten Mine, while initiating a major recapitalisation plan to stabilise finances and leadership.

Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.